125 related articles for article (PubMed ID: 6630105)
1. Netilmicin 150 mg every 12 hours in systemic infections.
Haverkorn MJ
J Antimicrob Chemother; 1983 Sep; 12(3):209-17. PubMed ID: 6630105
[TBL] [Abstract][Full Text] [Related]
2. Netilmicin 200 mg twice a day for adult patients with life-threatening infections. A preliminary report.
Perera MR; Amirak ID; Noone P
Scand J Infect Dis Suppl; 1980; Suppl 23():186-8. PubMed ID: 6937966
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of netilmicin-cefoxitin and gentamicin-cefoxitin in surgical patients with serious systemic infection.
Bubrick MP; Howard RJ; Pancorbo S; Lorber RR; Chin TW; Yost R
Clin Ther; 1983; 5(5):515-24. PubMed ID: 6352035
[TBL] [Abstract][Full Text] [Related]
4. Infection with netilmicin resistant Serratia marcescens in a special care baby unit.
Lewis DA; Hawkey PM; WattsJA ; Speller DC; Primavesi RJ; Fleming PJ; Pitt TL
Br Med J (Clin Res Ed); 1983 Dec; 287(6406):1701-5. PubMed ID: 6315130
[TBL] [Abstract][Full Text] [Related]
5. High dose netilmicin therapy of severe or chronic infections.
Hellum KB; Madsen ST; Digranes A; Stokstad S; Solberg CO
Scand J Infect Dis Suppl; 1980; Suppl 23():189-94. PubMed ID: 6937967
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of netilmicin, 150 mg BID, in systemic infections.
Tambic T; Kropec I; Kosuta D
Clin Ther; 1981; 4(1):43-7. PubMed ID: 7023679
[TBL] [Abstract][Full Text] [Related]
7. Netilmicin therapy of serious Gram-negative bacillary infections.
Edelstein PH; Meyer RD
J Antimicrob Chemother; 1978 Nov; 4(6):495-502. PubMed ID: 711647
[No Abstract] [Full Text] [Related]
8. Evaluation of netilmicin susceptibility discs using bacteria with known aminoglycoside resistance patterns: correlation of in vitro and in vivo test results.
Waitz JA; Hare RS; Moss EL; Sabatelli FJ; Schaffer TW; Waitz JA
Scand J Infect Dis Suppl; 1980; Suppl 23():62-72. PubMed ID: 6937970
[TBL] [Abstract][Full Text] [Related]
9. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin.
Verpooten GA; Giuliano RA; Verbist L; Eestermans G; De Broe ME
Clin Pharmacol Ther; 1989 Jan; 45(1):22-7. PubMed ID: 2910634
[TBL] [Abstract][Full Text] [Related]
10. Netilmicin in urinary tract infections.
Svare J; Johnsen NJ; Vesterhauge S; Lund F; Thomsen J; Vejlsgaard R
Scand J Infect Dis Suppl; 1980; Suppl 23():132-4. PubMed ID: 6937957
[TBL] [Abstract][Full Text] [Related]
11. Netilmicin: its in vitro activity and synergism with penicillin compounds.
Thadepalli H; Roy I
Chemotherapy; 1980; 26(1):12-20. PubMed ID: 7353438
[TBL] [Abstract][Full Text] [Related]
12. Nephrotoxicity, high frequency ototoxicity, efficacy and serum kinetics of once versus thrice daily dosing of netilmicin in patients with serious infections.
Blaser J; Simmen HP; Thurnheer U; König C; Lüthy R
J Antimicrob Chemother; 1995 Nov; 36(5):803-14. PubMed ID: 8626261
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of netilmicin in comparison with gentamicin, sisomicin, tobramycin, and amikacin and their resistance patterns.
Braveny I; Voeckl J; Machka K
Arzneimittelforschung; 1980; 30(3):491-5. PubMed ID: 7387761
[TBL] [Abstract][Full Text] [Related]
14. Once-daily gentamicin versus once-daily netilmicin in patients with serious infections--a randomized clinical trial.
Prins JM; Büller HR; Kuijper EJ; Tange RA; Speelman P
J Antimicrob Chemother; 1994 Apr; 33(4):823-35. PubMed ID: 8056701
[TBL] [Abstract][Full Text] [Related]
15. Multicenter comparative evaluation of netilmicin and gentamicin in adult patients. Efficacy and safety.
Herting RL; Lorber RR; Miller M; Danzig MR
Arzneimittelforschung; 1981; 31(2):366-70. PubMed ID: 7194655
[TBL] [Abstract][Full Text] [Related]
16. Combination effect of cefmenoxime with four aminoglycosides on Enterobacteriaceae susceptible and moderately susceptible to this new cephalosporin.
Husson MO; Izard D; Bryskier A; Vincent P; Leclerc H
Zentralbl Bakteriol Mikrobiol Hyg A; 1984 Aug; 257(3):383-7. PubMed ID: 6091368
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of cefotiam combinations against Enterobacteriaceae moderately susceptible or resistant to this new cephalosporin.
Husson MO; Izard D; Leclerc H
Drugs Exp Clin Res; 1986; 12(4):325-7. PubMed ID: 3459642
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomised comparison of cefotaxime vs. netilmicin vs. cefotaxime plus netilmicin in the treatment of hospitalised patients with serious sepsis.
Sage R; Nazareth B; Noone P
Scand J Infect Dis; 1987; 19(3):331-7. PubMed ID: 3616496
[TBL] [Abstract][Full Text] [Related]
19. Changes in resistance to aminoglycoside antibiotics of different bacterial strains isolated during the period 1978 to 1983. Netilmicin as alternative therapy.
Bovelacci A; Montini G; Ramacciotti PG
Chemioterapia; 1985 Dec; 4(6):439-44. PubMed ID: 3830413
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of netilmicin, amikacin, tobramycin and sisomicin against gentamicin highly-resistant enterobacteriaceae.
Tselentis J; Legakis NJ; Nicolas KJ; Melissinos K; Papavassiliou J
Chemotherapy; 1980; 26(6):409-17. PubMed ID: 7408554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
